AlzGene - Gene overview of all published AD-association studies for IL6
Back Search Methods Disclaimer Credits
 Gene: IL6  (HGF; HSF; BSF2; IL-6; IFNB2)  Entrez Gene    View on MSGene   View on PDGene   View on SZGene
 Protein: interleukin 6 (interferon, beta 2)   ProteinLink
 Chromosome: 7   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Arosio, 2004
Italy (Milan) CL  1  (detail)  65
(68%)
C-80 + 2
(-)
65
(62%)
82 + 2
(-)
Positive
Bagli, 2000
Overlaps with
Combarros, 2009 (Germany)
CL  1  (detail)  102
(67%)
C-74.4 + 10.3
(51-101)
351
(58%)
69.3 + 9.6
(50-100)
n.a.
Bagli, 2000
Germany CL  1  (detail)  102
(67%)
C-74.4 + 10.3
(51-101)
351
(58%)
69.3 + 9.6
(50-100)
Trend
Bagli, 2003
Overlaps with
Combarros, 2009 (Germany)
CL  1  (detail)  58
(62%)
C-71.2 + 8.6
(-)
25
(56%)
65.4 + 10.5
(-)
n.a.
Bhojak, 2000
USA CL  1  (detail)  531
(65%)
M71.8 + 7.9
(-)
76.1 + 7.1
(-)
337
(-)
74 + 4.7
(-)
Negative
Capurso, 2004
Overlaps with
Capurso, 2009
CL  1  (detail)  168
(64%)
C69.7 + 9.6
(-)
-220
(67%)
75.4 + 8.5
(-)
n.a.
Capurso, 2009
Italy (Apulia) CL  2  (detail)  149
(64%)
C70.2 + 9.9
(-)
-298
(57%)
68.9 + 17.1
(-)
Negative
Combarros, 2005
Overlaps with
Combarros, 2009 (Santander)
CL  1  (detail)  234
(67%)
C71.7 + 8.3
(48-95)
75.1 + 8.3
(50-98)
197
(71%)
79.8 + 7.9
(63-98)
n.a.
Combarros, 2009
Germany CL  2  (detail)  259
(61%)
C-71
(-)
232
(57%)
67.8
(-)
Positive
Combarros, 2009
Netherlands PO  2  (detail)  391
(75%)
C-86.6
(-)
5111
(58%)
76.9
(-)
Positive
Combarros, 2009
Spain (Santander) CL  2  (detail)  351
(65%)
C-75.5
(-)
396
(69%)
80.9
(-)
Positive
Combarros, 2009
UK (Bristol) CL  2  (detail)  200
(45%)
N-80.4
(-)
57
(40%)
77.9
(-)
Positive
Combarros, 2009
UK (Nottingham) CL  2  (detail)  104
(48%)
N-78.7
(-)
107
(35%)
72.5
(-)
Positive
Combarros, 2009
UK (OPTIMA) CL  2  (detail)  250
(54%)
M-79.4
(-)
261
(54%)
78.9
(-)
Positive
Combarros, 2009
Spain (Oviedo) CL  2  (detail)  202
(70%)
C-78.4
(-)
131
(62%)
69.7
(-)
Positive
Cousin, 2009
France CL  1  (detail)  428
(-)
C64.9 + 9.9
(-)
-475
(-)
66.2 + 10.8
(-)
Negative
Depboylu, 2004
Germany CL  1  (detail)  113
(-)
C-69.8 + 9.1
(51-90)
108
(-)
68.4 + 10.4
(50-93)
Negative
Faltraco, 2003
Germany PO  1  (detail)  101
(60%)
C-72.5 + 9.6
(-)
133
(50%)
48.9 + 12.6
(-)
Positive
Fontalba, 2009
Overlaps with
Combarros, 2009 (Santander)
CL  1  (detail)  239
(66%)
C72.4 + 7.9
(48-94)
75.6 + 7.8
(50-97)
165
(69%)
80.8 + 7.1
(63-98)
n.a.
Giedraitis, 2009
Sweden (ULSAM) CL  2  (detail)  86
(0%)
C80.2
(72-85)
-404
(0%)
81.8
(80-84)
Negative
Infante, 2004
Overlaps with
Combarros, 2009 (Santander)
CL  1  (detail)  232
(67%)
C72.1 + 8.1
(48-95)
75.6 + 8.2
(50-98)
191
(71%)
79.9 + 7.5
(63-98)
n.a.
Koivisto, 2005
Finland CL  1  (detail)  65
(72%)
C-77.6 + 2.8
(-)
542
(64%)
76.4 + 2.8
(-)
Positive
Li, 2008
Canada CL  2  (detail)  753
(58%)
C71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Negative
Licastro, 2003
Italy (Bologna) CL  2  (detail)  332
(64%)
M-71.8 + 8
(-)
393
(48%)
76 + 14
(-)
Positive
Licastro, 2006
Overlaps with
Licastro, 2003
CL  1  (detail)  260
(-)
C--190
(-)
-n.a.
Mateo, 2005
Overlaps with
Combarros, 2009 (Santander)
CL  1  (detail)  266
(68%)
C71.6 + 9
(48-95)
75.4 + 9.1
(50-98)
273
(71%)
80.3 + 7.8
(63-100)
n.a.
Papassotiropoulos, 1999
Overlaps with
Combarros, 2009 (Germany)
CL  1  (detail)  102
(67%)
C-74.4 + 10.3
(51-101)
191
(52%)
70.6 + 11.4
(50-100)
n.a.
Paradowski, 2008
Poland CL  1  (detail)  51
(67%)
C-73 + 6.9
(-)
36
(81%)
73.5 + 8.2
(-)
Negative
Pola, 2002
Italy (Rome) CL  1  (detail)  124
(62%)
C-77 + 5.5
(-)
134
(54%)
76 + 6.7
(-)
Positive
Ravaglia, 2005
Italy (Ravenna) CO  1  (detail)  105
(73%)
C-80.6 + 7.8
(-)
644
(52%)
73 + 5.9
(-)
Negative
van Oijen, 2006
Overlaps with
Combarros, 2009 (Netherlands)
PO  1  (detail)  583
(-)
C--6303
(-)
-n.a.
Zhang, 2004
UK CL  1  (detail)  356
(60%)
M63.9 + 10.4
(-)
-434
(-)
65.8 + 14.2
(-)
Negative
 Asian
He, 2009
China CL  2  (detail)  318
(43%)
C71.3 + 8.6
(-)
80.8 + 6.8
(-)
324
(44%)
80.6 + 7.3
(-)
Positive
Nishimura, 2004
Japan CL  1  (detail)  172
(60%)
C-77.4 + 9.7
(55-96)
163
(61%)
75.5 + 9.9
(-)
Negative
Shibata, 2002
Japan CL  2  (detail)  128
(-)
C-70.5 + 9.6
(-)
83
(-)
69.1 + 9.4
(-)
Positive
 Other/Mixed
Vural, 2009
Turkey CL  1  (detail)  101
(65%)
C71.4
(-)
76.3 + 6.8
(65-99)
138
(67%)
73.1 + 6.9
(62-94)
Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD

The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.